<pre>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="Publisher">
			<PMID Version="1">28521298</PMID>
			<DateCreated>
				<Year>2017</Year>
				<Month>05</Month>
				<Day>18</Day>
			</DateCreated>
			<DateRevised>
				<Year>2017</Year>
				<Month>05</Month>
				<Day>18</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1949-2553</ISSN>
					<JournalIssue CitedMedium="Internet">
						<PubDate>
							<Year>2017</Year>
							<Month>May</Month>
							<Day>04</Day>
						</PubDate>
					</JournalIssue>
					<Title>Oncotarget</Title>
					<ISOAbbreviation>Oncotarget</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.</ArticleTitle>
				<ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.17617</ELocationID>
				<Abstract>
					<AbstractText>Malignant rhabdoid tumors (MRTs) are rare, lethal, pediatric tumors predominantly found in the kidney, brain and soft tissues. MRTs are driven by loss of tumor suppressor SNF5/INI1/SMARCB1/BAF47. The prognosis of MRT is poor using currently available treatments, so new treatment targets need to be identified to expand treatment options for patients experiencing chemotherapy resistance. The growth hormone insulin-like growth factor 2 (IGF2) signaling pathway is a promising target to overcome drug resistance in many cancers. Here, we evaluated the role of IGF2 axis in MRT cell proliferation. We showed that microenvironment stress, including starvation treatment and chemotherapy exposure, lead to elevated expression of IGF2 in the SNF5-deficient MRT cell line. The autocrine IGF2, in turn, activated insulin-like growth factor 1 receptor (IGF1R), insulin receptor (INSR), followed by PI3K/AKT pathway and RAS/ERK pathway to promote cancer cell proliferation and survival. We further demonstrated that impairment of IGF2 signaling by IGF2 neutralizing antibody, IGF1R inhibitor NVP-AEW541 or AKT inhibitor MK-2206 2HCl treatment prevented MRT cell growth in vitro. Taken together, our characterization of this axis defines a novel mechanism for MRT cell growth in the microenvironment of stress. Our results also demonstrated the necessity to test the treatment effect targeting this axis in future research.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Li</LastName>
						<ForeName>Ting</ForeName>
						<Initials>T</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Cell Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Laboratory of Epigenetics in Development and Tumorigenesis, Tianjin Research Center of Basic Medical Sciences, Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Wang</LastName>
						<ForeName>Jin</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Cell Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Laboratory of Epigenetics in Development and Tumorigenesis, Tianjin Research Center of Basic Medical Sciences, Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Liu</LastName>
						<ForeName>Pengfei</ForeName>
						<Initials>P</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Lymphoma, Sino-Us Center of Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\'s Clinical Research Center for Cancer, Tianjin 300060, China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Chi</LastName>
						<ForeName>Jiadong</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Yan</LastName>
						<ForeName>Han</ForeName>
						<Initials>H</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Cell Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Laboratory of Epigenetics in Development and Tumorigenesis, Tianjin Research Center of Basic Medical Sciences, Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lei</LastName>
						<ForeName>Lei</ForeName>
						<Initials>L</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Cell Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Laboratory of Epigenetics in Development and Tumorigenesis, Tianjin Research Center of Basic Medical Sciences, Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Li</LastName>
						<ForeName>Zexing</ForeName>
						<Initials>Z</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Cell Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Laboratory of Epigenetics in Development and Tumorigenesis, Tianjin Research Center of Basic Medical Sciences, Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Yang</LastName>
						<ForeName>Bing</ForeName>
						<Initials>B</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Cell Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Laboratory of Epigenetics in Development and Tumorigenesis, Tianjin Research Center of Basic Medical Sciences, Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Wang</LastName>
						<ForeName>Xi</ForeName>
						<Initials>X</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Cell Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Laboratory of Epigenetics in Development and Tumorigenesis, Tianjin Research Center of Basic Medical Sciences, Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University, Tianjin 300070, China.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2017</Year>
					<Month>05</Month>
					<Day>04</Day>
				</ArticleDate>
				<Analyze>
					<Word>
						<Name>growth</Name>
						<Number>7</Number>
					</Word>
					<Word>
						<Name>igf2</Name>
						<Number>6</Number>
					</Word>
					<Word>
						<Name>treatment</Name>
						<Number>5</Number>
					</Word>
					<Word>
						<Name>mrt</Name>
						<Number>5</Number>
					</Word>
					<Word>
						<Name>cell</Name>
						<Number>5</Number>
					</Word>
					<Word>
						<Name>axis</Name>
						<Number>4</Number>
					</Word>
					<Word>
						<Name>stress</Name>
						<Number>3</Number>
					</Word>
					<Word>
						<Name>pathway</Name>
						<Number>3</Number>
					</Word>
					<Word>
						<Name>microenvironment</Name>
						<Number>3</Number>
					</Word>
					<Word>
						<Name>insulin-like</Name>
						<Number>3</Number>
					</Word>
					<Word>
						<Name>factor</Name>
						<Number>3</Number>
					</Word>
					<Word>
						<Name>tumors</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>tumor</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>signaling</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>rhabdoid</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>resistance</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>receptor</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>proliferation</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>mrts</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>malignant</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>inhibitor</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>igf1r</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>demonstrated</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>chemotherapy</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>akt</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>activated</Name>
						<Number>2</Number>
					</Word>
					<Word>
						<Name>vitro</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>using</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>turn</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>treatments</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>tissues</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>test</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>targets</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>targeting</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>target</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>taken</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>survival</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>suppressor</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>supports</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>starvation</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>soft</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>snf5-deficient</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>snf5</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>smarcb1</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>showed</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>serum-independent</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>role</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>results</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>research</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>ras</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>rare</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>promote</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>promising</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>prognosis</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>prevented</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>predominantly</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>poor</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>pi3k</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>pediatric</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>patients</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>overcome</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>options</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>nvp-aew541</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>novel</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>new</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>neutralizing</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>need</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>necessity</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>mk-2206</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>mechanism</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>loss</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>line</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>lethal</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>lead</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>kidney</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>insulin</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>insr</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>ini1</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>including</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>impairment</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>identified</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>hormone</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>future</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>followed</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>expression</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>exposure</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>experiencing</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>expand</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>evaluated</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>erk</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>elevated</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>effect</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>drug</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>driven</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>defines</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>currently</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>characterization</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>cancers</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>cancer</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>brain</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>baf47</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>available</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>autocrine</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>antibody</Name>
						<Number>1</Number>
					</Word>
					<Word>
						<Name>2hcl</Name>
						<Number>1</Number>
					</Word>
				</Analyze>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Oncotarget</MedlineTA>
				<NlmUniqueID>101532965</NlmUniqueID>
				<ISSNLinking>1949-2553</ISSNLinking>
			</MedlineJournalInfo>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">IGF axis</Keyword>
				<Keyword MajorTopicYN="N">insulin-like growth factor 1 receptor (IGF1R)</Keyword>
				<Keyword MajorTopicYN="N">insulin-like growth factor 2 (IGF2)</Keyword>
				<Keyword MajorTopicYN="N">malignant rhabdoid tumor (MRT)</Keyword>
				<Keyword MajorTopicYN="N">microenvironment stress</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2016</Year>
					<Month>11</Month>
					<Day>17</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2017</Year>
					<Month>04</Month>
					<Day>18</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2017</Year>
					<Month>5</Month>
					<Day>19</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2017</Year>
					<Month>5</Month>
					<Day>19</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2017</Year>
					<Month>5</Month>
					<Day>19</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>aheadofprint</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">28521298</ArticleId>
				<ArticleId IdType="pii">17617</ArticleId>
				<ArticleId IdType="doi">10.18632/oncotarget.17617</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
</pre>